Fund Name | Location |
Avlar BioVentures | Cambridgeshire, Madingley, United Kingdom |
Bialla Venture Partners | Maryland, Severna Park, United States |
Carmignac | France, Ile-de-France, Paris |
Ganfeng Lithium | China, Jiangxi, Xinyu |
Green Tomato | China, Hong Kong, Kowloon |
Hanover Technology Investment Management | California, Menlo Park, United States |
Hokuetsu Bank | Japan, Nagaoka, Niigata Prefecture |
InnoLinks Ventures | United States, Virginia, Virginia Beach |
InvictaWatch.com | Florida, Hollywood, United States |
Kokusai Kogyo | Japan, Tokyo |
Light Bridge Ventures | California, Santa Clara, United States |
Phoenix VC | Dubai, United Arab Emirates |
Princeton Alumni Angels | - |
Synergy Capital Management | China, Guangdong, Shenzhen |
The Angels' Forum | California, Mountain View, United States |
Tus-S&T Service Group | Beijing, Beijing, China |
Xuzhou Handler Special Vehicle | China, Jiangsu, Xuzhou |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Helexva | $2M | 02 Mar 2024 | Pittsburgh, Pennsylvania, United States | ||
Elektra Health | $3M | 21 Feb 2024 | New York, New York, United States | ||
Sudo Biosciences | $30M | 13 Feb 2024 | Menlo Park, California, United States | ||
Sempre Health | $20M | 13 Sep 2023 | San Francisco, California, United States | ||
Mozart Therapeutics | $25M | 07 Jun 2023 | - | ||
Ring Therapeutics | $86M | 09 Mar 2023 | Cambridge, Massachusetts, United States | ||
Noema Pharma | $112M | 07 Mar 2023 | Basel, Basel-City, Switzerland | ||
Cerevance | $51M | 13 Feb 2023 | Cambridge, Massachusetts, United States | ||
Smile CDR | $30M | 26 Jan 2023 | Toronto, Ontario, Canada |
– Smile CDR, Inc. from Toronto develops a data storage and integration platform to strengthen the health industry using the Health Level Seven (HL7®) Fast Healthcare Interoperability Resources (FHIR®) standard.
– The company raised $20m in Series A funding round led by 30 North Group and UPMC Enterprises.
– The new investment will be used to expand operations and business reach.
– Ring Therapeutics is a Cambridge, Mass.-based life sciences company.
– The company raised $117m in Series B funding.
– Backers included Invus, Altitude Life Science Ventures, Partners Investment, UPMC Enterprises, alongside Flagship Pioneering.
– The new investment will be used for the continued development and expansion of its novel vector Anellogy™ platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Helexva | $2M | 02 Mar 2024 | Pittsburgh, Pennsylvania, United States | ||
Elektra Health | $3M | 21 Feb 2024 | New York, New York, United States | ||
Sudo Biosciences | $30M | 13 Feb 2024 | Menlo Park, California, United States | ||
Sempre Health | $20M | 13 Sep 2023 | San Francisco, California, United States | ||
Mozart Therapeutics | $25M | 07 Jun 2023 | - | ||
Ring Therapeutics | $86M | 09 Mar 2023 | Cambridge, Massachusetts, United States | ||
Noema Pharma | $112M | 07 Mar 2023 | Basel, Basel-City, Switzerland | ||
Cerevance | $51M | 13 Feb 2023 | Cambridge, Massachusetts, United States | ||
Smile CDR | $30M | 26 Jan 2023 | Toronto, Ontario, Canada |